Meta-Analysis: Therapeutic Effect of Transcatheter Arterial Chemoembolization Combined with Compound Kushen Injection in Hepatocellular Carcinoma

Sun, Qizhe; Ma, Wei; Gao, Yuan; Zheng, Whenling; Bao, Zhenan; Peng, Yifei

doi:10.4314/ajtcam.v9i2.1

Cited by 25 publications

(19 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While the potent effects of FKI in clinical settings are beginning to undergo quantitative statistical analysis [47], the quality and reproducibility of FKI preparations remains in question. These are common concerns with many traditional Chinese medicinals.…”

Section: Discussionmentioning

confidence: 99%

Fufang Kushen injection inhibits sarcoma growth and tumor-induced hyperalgesia via TRPV1 signaling pathways

et al. 2014

View full text Add to dashboard Cite

Cancer pain is a deleterious consequence of tumor growth and related inflammation. Opioids and antiinflammatory drugs provide first line treatment for cancer pain, but both are limited by side effects. Fufang Kushen injection (FKI) is GMP produced, traditional Chinese medicine used alone or with chemotherapy to reduce cancer-associated pain. FKI limited mouse sarcoma growth both in vivo and in vitro, in part, by reducing the phosphorylation of ERK and AKT kinases and BAD. FKI inhibited TRPV1 mediated capsaicin-induced ERK phosphorylation and reduced tumor-induced proinflammatory cytokine production. Thus, FKI limited cancer pain both directly by blocking TRPV1 signaling and indirectly by reducing tumor growth.

show abstract

Section: Discussionmentioning

confidence: 99%

Fufang Kushen injection inhibits sarcoma growth and tumor-induced hyperalgesia via TRPV1 signaling pathways

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Recently, Sun et al observed that CKI plus transcatheter arterial chemoembolization (TACE) is superior to TACE alone. They suggested that CKI could be a complementary drug with TACE to inhibit the growth of hepatocellular carcinoma, suppress tumor metastasis, reduce the incidence of pain and improve the quality of life in patients with unresectable hepatocellular carcinoma [31] . Bao et al have conducted a systematic literature research, which revealed a positive effect of CKI on bone cancer pain: compared with radiotherapy or bisphosphonates, CKI showed significant effects on the improvement of pain relief in patients with bone cancer pain and the increase in Karnofsky scores (KPS).…”

Section: Studies On Compound Kushen Injectionmentioning

confidence: 99%

Anti-tumor activities of active ingredients in Compound Kushen Injection

Wang¹,

et al. 2015

View full text Add to dashboard Cite

Kushen (Radix Sophorae Flavescentis) has a long history of use for the treatment of tumors, inflammation and other diseases in traditional Chinese medicine. Compound Kushen Injection (CKI) is a mixture of natural compounds extracted from Kushen and Baituling (Rhizoma Smilacis Glabrae). The main principles of CKI are matrine (MT) and oxymatrine (OMT) that exhibit a variety of pharmacological activities, including anti-inflammatory, anti-allergic, anti-viral, anti-fibrotic and cardiovascular protective effects. Recent evidence shows that these compounds also produce anti-cancer actions, such as inhibiting cancer cell proliferation, inducing cell cycle arrest, accelerating apoptosis, restraining angiogenesis, inducing cell differentiation, inhibiting cancer metastasis and invasion, reversing multidrug resistance, and preventing or reducing chemotherapy-and/or radiotherapy-induced toxicity when combined with chemotherapeutic drugs. In this review, we summarize recent progress in studying the anti-cancer activities of MT, OMT and CKI and their potential molecular targets, which provide clues and references for further study.

show abstract

“…Six meta-analyses compared the outcomes of TACE in combination with TCMs versus TACE alone [18–19, 79, 81, 108, 122]. Three of them favored the combination therapy in term of OS [18, 79, 108]; one favored the combination therapy in terms of 1-, 2-, and 3-year survival, but not 6-month survival [19]; one favored the combination therapy in term of 2-year survival, but not 1-year survival [122]; one did not report the survival data [81].…”

Section: Tacementioning

confidence: 99%

“…Four of them favored the combination therapy in term of quality of life [18–19, 79, 108]. Another two did not report the relevant data [81, 122].…”

Section: Tacementioning

confidence: 99%

Management of hepatocellular carcinoma: an overview of major findings from meta-analyses

Zhao

et al. 2016

Oncotarget

View full text Add to dashboard Cite

This paper aims to systematically review the major findings from meta-analyses comparing different treatment options for hepatocellular carcinoma (HCC). A total of 153 relevant papers were searched via the PubMed, EMBASE, and Cochrane library databases. They were classified according to the mainstay treatment modalities (i.e., liver transplantation, surgical resection, radiofrequency ablation, transarterial embolization or chemoembolization, sorafenib, and others). The primary outcome data, such as overall survival, diseases-free survival or recurrence-free survival, progression-free survival, and safety, were summarized. The recommendations and uncertainties regarding the treatment of HCC were also proposed.

show abstract

Meta-Analysis: Therapeutic Effect of Transcatheter Arterial Chemoembolization Combined with Compound Kushen Injection in Hepatocellular Carcinoma

Abstract: Compound Kushen Injection (CKI) is Sophora flavescens and Heterosmilacis japonicae extract. Meta-analysis confirmed that CKI plus transcatheter arterial chemoembolization (TACE) is more superior to TACE alone for unresectable hepatocellular carcinoma (UHCC) patients.

Cited by 25 publications

References 9 publications

Fufang Kushen injection inhibits sarcoma growth and tumor-induced hyperalgesia via TRPV1 signaling pathways

Fufang Kushen injection inhibits sarcoma growth and tumor-induced hyperalgesia via TRPV1 signaling pathways

Anti-tumor activities of active ingredients in Compound Kushen Injection

Management of hepatocellular carcinoma: an overview of major findings from meta-analyses

Contact Info

Product

Resources

About